

## Recombinant Human BAFF (carrier-free)

<b>Catalog# / Size</b>	559608 / 500 µg 559602 / 10 µg 559604 / 25 µg 559606 / 100 µg
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	B cell activating factor belonging to the TNF family (BAFF), B lymphocytes stimulator (BLyS), TNF- and APOL-related leucocyte expressed ligand 1(TALL1), TNF homolog that activates apoptosis, NKFB, JNK (THANK), TNF13B, CD257
<b>Description</b>	BAFF is a TNF- $\alpha$ cytokine member (a type II membrane protein) that acts in both a membrane-bound form and soluble cytokine form. The extracellular domain of BAFF shows high homology with APRIL. The soluble form is derived by cleavage in a furin consensus site. In human neutrophils treated with G-CSF, BAFF is processed intracellularly by a furin-type convertase. BAFF acts mainly as a soluble trimer and binds to three receptors with decreasing affinity in the following order: BAFFR > TACI > BCMA. Mice deficient in BAFF or its receptor BAFFR exhibit an obstruction in B cell development after the transitional T1 stage and lack marginal zone (MZ) and conventional B2 B cells. BAFFR-deficient mice and humans (patients with common variable immunodeficiency, or CVID) develop severe B cell lymphopenia due to the arrest of B cell development at the transitional B cell stage. Extreme BAFF production triggers severe autoimmune disorders in mice similar to Systemic Lupus Erythematosus (SLE) and Sjögren's syndrome. BAFF has been associated with different human diseases such as pancreatic ductal adenocarcinoma (PDAC), autoimmune pancreatitis, SLE, rheumatoid arthritis, Sjögren's syndrome, lymphoid cancers, HIV infection, and B cell malignancies such as non-Hodgkin's lymphoma (NHL).

### Product Details

---

<b>Source</b>	Human BAFF, amino acids (Ala134-Leu285) (Accession# NM_006573), was expressed with a N-terminal 9-His tag in CHO cells.
<b>Molecular Mass</b>	The 173 amino acid recombinant protein has a predicted molecular mass of approximately 19.2 kD. The protein migrates at approximately 20 kD in DTT-reducing and non-reducing conditions by SDS-PAGE. The predicted N-terminal amino acid is His.
<b>Purity</b>	>95%, as determined by Coomassie stained SDS-PAGE.
<b>Formulation</b>	0.22 µm filtered protein solution is in 20mM NaHPO <sub>4</sub> , 300mM NaCl, 2mM DTT, 1mM EDTA, 2mM CHAPS, and in pH 6.0.
<b>Endotoxin Level</b>	Less than 1 EU per µg cytokine as determined by the LAL method.
<b>Concentration</b>	10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.
<b>Storage &amp; Handling</b>	Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. <b>Avoid repeated freeze/thaw cycles.</b>
<b>Activity</b>	ED <sub>50</sub> = 0.3 - 2.0 ng/mL, corresponding to a specific activity of 0.5 - 3.33 x 10 <sup>6</sup> units/mg, as determined by the dose dependent stimulation of mouse B cells proliferation.
<b>Application</b>	<a href="#">Bioassay</a>
<b>Application Notes</b>	BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our <a href="#">100% satisfaction guarantee</a> . If you have any

concerns, contact us at [tech@biolegend.com](mailto:tech@biolegend.com).

## Product Citations

1. Jenks SA *et al.* 2018. *Immunity*. 49(4):725-739 . [PubMed](#)


## Antigen Details

---

<b>Structure</b>	Cytokine.
<b>Distribution</b>	Monocytes, macrophages, dendritic cells, neutrophils, and stromal cells of lymphoid organs.
<b>Function</b>	BAFF induces B cell maturation, proliferation, survival, and immunoglobulin production. BAFF controls the size and composition of mature preimmune B cell pools. BAFF is induced by INF- $\gamma$ in monocytes.
<b>Interaction</b>	Immature B cells, peripheral B-cells, na $\tilde{A}^-$ ve and memory cells.
<b>Ligand/Receptor</b>	BAFFR, TACI (transmembrane activator and calcium-modulator and cyclophilin ligand interactor), and BCMA (B cell maturation antigen).
<b>Bioactivity</b>	Induces B cell proliferation.
<b>Cell Type</b>	Embryonic Stem Cells
<b>Biology Area</b>	Cell Biology, Costimulatory Molecules, Immunology, Signal Transduction, Stem Cells
<b>Molecular Family</b>	CD Molecules, Cytokines/Chemokines, Growth Factors, Soluble Receptors
<b>Antigen References</b>	<ol style="list-style-type: none"><li>1. Schneider P, <i>et al.</i> 1999. <i>J. Exp. Med.</i> 189:1747.</li><li>2. Nardelli B, <i>et al.</i> 2001. <i>Blood</i> 97:198.</li><li>3. Schiemann B, <i>et al.</i> 2001. <i>Science</i> 5537:2111.</li><li>4. Scapini P, <i>et al.</i> 2003. <i>J. Exp. Med.</i> 197:297.</li><li>5. Yeramilli VA and Knight KL. 2010. <i>J. Immunol.</i> 184:5527.</li><li>6. Scholz JL and Cancro MP. 2012. <i>Immunol. Lett.</i> 143:2.</li><li>7. Sindhava VJ, <i>et al.</i> 2013. <i>Front Immunol.</i> 4:37.</li><li>8. Koizumi M, <i>et al.</i> 2013. <i>PLoS One</i> 8(8):e71367.</li></ol>
<b>Gene ID</b>	<a href="#">10673</a>

## Product Data

---



IgM-stimulated mouse B cell proliferation induced by human BAFF.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587